| Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED |
2019-10-10 |
| Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
| Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies |
2019-10-09 |
| GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies |
2019-10-08 |
| Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity |
2019-10-07 |
| Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |
| Korro Bio–New Enterprise Associates: investment, 201910 existing investor NEA |
2019-10-07 |
| Aeovian Pharmaceuticals–Apollo Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo Health Ventures |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Aeovian Pharmaceuticals–MacDougall Biomedical Communications: public relations, 201910 service existent by MacDougall |
2019-10-03 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners |
2019-10-03 |
| Frequency Therapeutics–SEVERAL: investment, 201910 IPO $84m+$12.6m with 6m+900k shares common stock at $14/share at Nasdaq Global Select Market |
2019-10-03 |
| Immunexpress–SEVERAL: investment, 201910 private financing round |
2019-10-03 |
| Congenica–Genomenon: genomic software tools, 201910– collab integration of Mastermind Genomic Search Engine into clinical decision support s/w |
2019-10-02 |
| Elicio Therapeutics–SEVERAL: investment, 201910 financing round Series B $33m incl Clal + Livzon + Efung Capital |
2019-10-02 |
| Freiberg Instruments–Bruker Corp: investment, 201910 acquisition €na of Magnettech EPR business by Bruker |
2019-10-02 |
| Frequency Therapeutics–Kendall Investor Relations: public relations, 201910 supply service existent IR by Kendall IR |
2019-10-02 |
| Frequency Therapeutics–ScientPR: public relations, 201910 supply service existent media relations by Scient Public Relations Inc |
2019-10-02 |
| Geneoscopy–SEVERAL: investment, 201910 financing round Series A $6.9m led by Cultivation Capital + NT Investments + incl Lightchain Capital |
2019-10-02 |
| SEngine Precision Medicine–SEVERAL: investment, 201910 financing round Series A $5.1m led by Bangarang Group with family offices + existing investors |
2019-10-02 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug r+d + commercialisation |
2019-10-01 |
| Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters |
2019-09-30 |
| Creoptix–Waters: investment, 201909 financing round Series 1st closing totalling CHF8m incl existing + co-investor Waters Corp |
2019-09-30 |
| Creoptix–Zürcher Kantonalbank: investment, 201909 financing round Series 1st closing totalling CHF8m incl new + lead investor Swisscanto Invest |
2019-09-30 |
| Roper Technologies–AMETEK: investment, 201909– acquisition $925m in cash of Gatan Inc from Roper Technologies by AMETEK |
2019-09-27 |
| Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) |
2019-09-24 |
| Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications |
2019-09-24 |
| AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS |
2019-09-20 |
| AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors |
2019-09-20 |
| Boehringer–Inflammasome: drug delivery technology, 201909– co-developm + license up to 3 retinal disease therapies using IVT drug delivery |
2019-09-20 |
| Bruker Corp–Murdoch Univ: analytical technologies, 201909– collab strategic alliance with ANPC incl MS + NMR for phenomics research |
2019-09-20 |
| Innate Pharma–SEVERAL: investment, 201909– filed US IPO + listing of ADSs at Nasdaq Global Market |
2019-09-20 |
| Murdoch Univ–Bruker Corp: NMR spectrometer, 201909 supply NMR FoodScreener |
2019-09-20 |
| Boundless Bio–Alexandria Real Estate: investment, 201909 financing round Series A totalling $46m incl co-investor Alexandria Venture Investments |
2019-09-19 |
| Boundless Bio–ARCH Venture: investment, 201909 financing round Series A totalling $46m incl co-lead investor ARCH Venture Partners |
2019-09-19 |
| Boundless Bio–City Hill Ventures: investment, 201909 financing round Series A totalling $46m incl co-lead investor City Hill Ventures |
2019-09-19 |
| Boundless Bio–GT Healthcare Capital Partners: investment, 201909 financing round Series A totalling $46m incl co-investor GT Healthcare CP |
2019-09-19 |
| Boundless Bio–SEVERAL: investment, 201909 financing round Series A $46m co-led by ARCH Venture Partners + City Hill Ventures |
2019-09-19 |
| Boundless Bio–Tavistock: investment, 201909 financing round Series A totalling $46m incl co-investor Boxer Capital |
2019-09-19 |
| Boundless Bio–Temasek: investment, 201909 financing round Series A totalling $46m incl co-investor Vertex Ventures |
2019-09-19 |
| Boundless Bio–WPP: public relations, 201909 service existent by Glover Park Group |
2019-09-19 |
| China (govt)–Agilent: grant, 201909– Thought Leader Award to Hualiang Jiang at SIMM CAS for work in medicinal chemistry + drug discovery |
2019-09-19 |
| Ginkgo Bioworks–Bateman Group: public relations, 201909 service existent by Bateman Group |
2019-09-19 |
| Ginkgo Bioworks–SEVERAL: investment, 201909 financing round Series E $290m incl funds + accounts advised by T Rowe Price Associates |
2019-09-19 |
| Ginkgo Bioworks–T Rowe Price Associates: investment, 201909 financing round Series E totalling $290m incl funds + accounts advised by T Rowe Price |
2019-09-19 |
| Menarini–BlueBee: bioinformatics, –201909 collab developm of MSBiosuite using BlueBee genomics data platoform |
2019-09-19 |
| Themis Bioscience–Farallon Capital: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Farallon Capital |
2019-09-18 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Bayer–Informed Data Systems: digital health, 201909– collab + licensing agreem $10m developm + commercialisaing of One Drop technology platform |
2019-09-17 |
| Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer |
2019-09-17 |
| Jounce Therapeutics–Yates Network: public relations, 201909 service existent by The Yates Network |
2019-09-17 |
| Alder Biopharmaceuticals–Lundbeck: investment, 201909 acquisition tender offer in cash + CVRs up to $1.95b net of cash ANNOUNCED |
2019-09-16 |
| Autolus–PPF Group: investment, 201909 acquisition 19.2% stake in market through Nasdaq by PPF Group NV |
2019-09-16 |
| Healthy.io–SEVERAL: investment, 201909 financing round Series C $60m led by Corner Ventures |
2019-09-12 |
| Inotrem–Invus Group: investment, 201909 financing round Series B totalling €39m incl co-investor Invus |
2019-09-12 |
| Inotrem–Morningside: investment, 201909 financing round Series B totalling €39m incl lead investor Morningside Ventures |
2019-09-12 |
| Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures |
2019-09-12 |
| SpringWorks Therapeutics–SEVERAL: investment, 201909 IPO $162m+$24.3m with 9m+1.35m shares common stock at $18/share at Nasdaq Global Select Market |
2019-09-12 |
| Atomwise–JPA Health Communications: public relations, 201909 service existent by JPA |
2019-09-11 |
| Avalon Ventures–GSK: investment, 201909 acquisition of Sitari Pharmaceuticals incubated 11/13 as part of GSK/Avalon collaboration |
2019-09-11 |
| Capella Therapeutics–Qianzhin Investment Management: investment, 201909 existing investor QZ |
2019-09-11 |
| Cedilla Therpapeutics–o2h: drug discovery services, 201909– collab expansion synthetic chemistry services for small molecules for protein regulation |
2019-09-11 |
| Denovo Biopharma–Qianzhin Investment Management: investment, 201909 existing investor QZ |
2019-09-11 |
| Hansoh Pharmaceutical–Atomwise: AI-based drug discovery, 201909– collab design + discover small-molecule drugs against 11 target proteins |
2019-09-11 |
| Agilent–Mobilion: mass spectrometry, 201909– collab integration of SLIM ion mobility technology with Agilent Q-TOF MS platform |
2019-09-10 |
| Atropos Therapeutics–Atomwise: AI-based drug discovery, 201909– collab launch joint venture r+d cancer drugs using senescence assay |
2019-09-10 |
| Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America |
2019-09-10 |
| Insilico Medicine–Baidu Ventures: investment, 201909 financing round Series B totalling $37m incl co-investor Baidu Ventures |
2019-09-10 |
| Insilico Medicine–BOLD Capital Partners: investment, 201909 financing round Series B totalling $37m incl co-investor BOLD Capital Partners |
2019-09-10 |
| Insilico Medicine–F-Prime: investment, 201909 financing round Series B totalling $37m incl co-investor F-Prime Capital |
2019-09-10 |
| Insilico Medicine–Fidelity: investment, 201909 financing round Series B totalling $37m incl co-investor Eight Roads |
2019-09-10 |
| Insilico Medicine–Lilly: investment, 201909 financing round Series B totalling $37m incl co-investor Lilly Asia Ventures |
2019-09-10 |
| Insilico Medicine–Pavilion Capital: investment, 201909 financing round Series B totalling $37m incl co-investor Pavilion Capital |
2019-09-10 |
| Insilico Medicine–Qiming: investment, 201909 financing round Series B totalling $37m incl lead investor Qiming Venture Partners |
2019-09-10 |
| Insilico Medicine–SEVERAL: investment, 201909 financing round Series B $37m led by Qiming Venture Partners |
2019-09-10 |
| Insilico Medicine–Sinovation Ventures: investment, 201909 financing round Series B totalling $37m incl co-investor Sinovation Ventures |
2019-09-10 |
| Mobilion–CG Life: public relations, 201909 service existent by CG Life |
2019-09-10 |
| Mobilion–United States (govt): mass spectrometry, 201909 license existent to LIMS technology from PNNL excl for life science applications |
2019-09-10 |
| OncoStatyx–Atomwise: AI-based drug discovery, 201909– collab launch joint venture to discover + develop small molecule KDM5B inhititors for cancer |
2019-09-10 |
| Pharvaris–Bain Capital: investment, 201909 financing round Series B totalling $66m incl new + co-investor Bain Capital Life Sciences |
2019-09-10 |
| Pharvaris–Foresite Capital: investment, 201909 financing round Series B totalling $66m incl new + lead investor Foresite Capital |
2019-09-10 |
| Pharvaris–Idinvest Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Idinvest Partners |
2019-09-10 |
| Pharvaris–Kurma: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Kurma Partners |
2019-09-10 |
| Pharvaris–Life Sciences Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor LSP |
2019-09-10 |
| Pharvaris–Rockefeller: investment, 201909 financing round Series B totalling $66m incl new + co-investor Venrock Partners |
2019-09-10 |
| Pharvaris–SEVERAL: investment, 201909 financing round Series B $66m led by Foresite Capital |
2019-09-10 |
| Pharvaris–VenBio: investment, 201909 financing round Series B totalling $66m incl new + co-investor venBio Partners |
2019-09-10 |
| SEngine Precision Medicine–Atomwise: AI-based drug discovery, 201909– collab launch joint venture r+d personalised cancer drugs using gene targets |
2019-09-10 |
| 4BIO Ventures–SEVERAL: investment, 201909 first closing $50m of 4BIO Ventures II fund targeting $150m |
2019-09-09 |
| BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market |
2019-09-09 |
| Cerevel–W2O Group: public relations, 201909 service existent by W2Opure |
2019-09-09 |
| Genmab–Tempus: AI-based drug discovery, 201909– strateg collab multi-year r+d targets + biomarker for personalised cancer drugs |
2019-09-09 |
| ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 |
2019-09-06 |
| Agilent–SEVERAL: credit, 201909–202909 public offering $500m net $492.8m Senior Notes 2.75% due Sept 2029 |
2019-09-05 |
| Invitae–SEVERAL: credit, 201909–20224 senior convertible notes $300m net $291.2m due 2024 at 2% |
2019-09-05 |
| Roche–Abionic: in vitro diagnostics, 201909– collab developm + supply abioSCOPE IVD PoC asthma test panel for asthma management in US for Genentech |
2019-09-05 |
| Sigrid Therapeutics–Joyance Partners: investment, 201909 financing round totalling $1.6m incl co-lead investor Joyance Partners |
2019-09-05 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
